S100A11 can also promote the proliferation and viability of pancreatic cancer cells by up-regulating the PI3K/AKT signaling pathway, which is considered to be a promising new drug target for targeted therapy of pancreatic cancer (Xiao et al., 2018). Here, AKT1 is linked to familial pancreatic carcinoma.